Production of Monoclonal Antibody, PR81, Recognizing the Tandem Repeat Region of MUC1 Mucin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Production of Monoclonal Antibody, PR81, Recognizing the Tandem Repeat Region of MUC1 Mucin

Published:2003-06 Issue:3 Volume:22 Page:153-158
ISSN:1536-8599
Container-title:Hybridoma and Hybridomics
language:en
Short-container-title:Hybridoma and Hybridomics

Author:

Paknejad M.¹,Rasaee M.J.²,Tehrani F. Karami²,Kashanian S.²,Mohagheghi M.A.³,Omidfar K.²,Bazl M. Rajabi²

Affiliation:

1. Tarbiat Modarres University, School of Medical Sciences, Department of Biochemistry, Tehran, Iran

2. Modarres University, School of Medical Sciences, Department of Biochemistry, Tehran, Iran. 2Cancer Institute, Tehran, Iran

3. Cancer Institute, Tehran, Iran

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/153685903322286566

Reference20 articles.

1. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats.

2. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin.

3. Epithelial Mucin Genes

4. Immunological and structural features of the protein core of human polymorphic epithelial mucin

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in MUC1-Mediated Breast Cancer Immunotherapy;Biomolecules;2022-07-06

2. Preparation and preclinical characterization of 111 In-DTPA-Anti-MUC1 as a radioimmunoconjugate for diagnosis of breast cancer by single-photon emission computed tomography;Journal of Cancer Research and Therapeutics;2022

3. Human absorbed dose estimation of ¹¹¹In-DOTA-PR81 as a novel high potential agent for breast cancer imaging;Journal of Medical Physics;2022

4. Preparation, quality control, and biodistribution assessment of [ 111 In]In‐DOTA‐PR81 in BALB/c mice bearing breast tumors;Journal of Labelled Compounds and Radiopharmaceuticals;2021-01-12

5. MUC1 antibody-based therapeutics: the promise of cancer immunotherapy;Immunotherapy;2020-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3